Receipt of cal-1 modified hematopoietic cellular products

Clinical trials for Receipt of cal-1 modified hematopoietic cellular products explained in plain language.

Never miss a new study

Get alerted when new Receipt of cal-1 modified hematopoietic cellular products trials appear

Sign up with your email to follow new studies for Receipt of cal-1 modified hematopoietic cellular products, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

HIV gene therapy passes first safety check in tiny study

Disease control Ongoing

This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study…

Matched conditions: RECEIPT OF CAL-1 MODIFIED HEMATOPOIETIC CELLULAR PRODUCTS

Sponsor: Calimmune, Inc. • Aim: Disease control

Last updated Jun 27, 2026 07:54 UTC

Receipt of cal-1 modified hematopoietic cellular products

Get alerted when new Receipt of cal-1 modified hematopoietic cellular products trials appear

HIV gene therapy passes first safety check in tiny study